These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 8095179

  • 1. Scytophycins, novel microfilament-depolymerizing agents which circumvent P-glycoprotein-mediated multidrug resistance.
    Smith CD, Carmeli S, Moore RE, Patterson GM.
    Cancer Res; 1993 Mar 15; 53(6):1343-7. PubMed ID: 8095179
    [Abstract] [Full Text] [Related]

  • 2. Reversal of multiple drug resistance by tolyporphin, a novel cyanobacterial natural product.
    Smith CD, Prinsep MR, Caplan FR, Moore RE, Patterson GM.
    Oncol Res; 1994 Mar 15; 6(4-5):211-8. PubMed ID: 7841544
    [Abstract] [Full Text] [Related]

  • 3. Microfilament depletion and circumvention of multiple drug resistance by sphinxolides.
    Zhang X, Minale L, Zampella A, Smith CD.
    Cancer Res; 1997 Sep 01; 57(17):3751-8. PubMed ID: 9288783
    [Abstract] [Full Text] [Related]

  • 4. Differential interactions of cytochalasins with P-glycoprotein.
    Zilfou JT, Smith CD.
    Oncol Res; 1995 Sep 01; 7(9):435-43. PubMed ID: 8835287
    [Abstract] [Full Text] [Related]

  • 5. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, Hamilton TC.
    Cancer Res; 1993 Nov 01; 53(21):5225-32. PubMed ID: 8106143
    [Abstract] [Full Text] [Related]

  • 6. Reversal of multidrug resistance by two novel indole derivatives.
    Kadam S, Maus M, Poddig J, Schmidt S, Rasmussen R, Novosad E, Plattner J, McAlpine J.
    Cancer Res; 1992 Sep 01; 52(17):4735-40. PubMed ID: 1355008
    [Abstract] [Full Text] [Related]

  • 7. Cryptophycin: a new antimicrotubule agent active against drug-resistant cells.
    Smith CD, Zhang X, Mooberry SL, Patterson GM, Moore RE.
    Cancer Res; 1994 Jul 15; 54(14):3779-84. PubMed ID: 7913408
    [Abstract] [Full Text] [Related]

  • 8. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
    Pan L, Tong Y, Jin Y, Zhou S, Zhang Y, Yang X, Mao N.
    Chin Med J (Engl); 2001 Sep 15; 114(9):929-32. PubMed ID: 11780384
    [Abstract] [Full Text] [Related]

  • 9. In vitro multidrug resistance of P388 murine leukemia selected for resistance to diaziquone.
    Gutierrez PL, Wilder PJ, Biswal N.
    Cancer Commun; 1989 Sep 15; 1(3):181-90. PubMed ID: 2576972
    [Abstract] [Full Text] [Related]

  • 10. Inhibitory effect of steroidal alkaloids on drug transport and multidrug resistance in human cancer cells.
    Lavie Y, Harel-Orbital T, Gaffield W, Liscovitch M.
    Anticancer Res; 2001 Sep 15; 21(2A):1189-94. PubMed ID: 11396162
    [Abstract] [Full Text] [Related]

  • 11. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
    Kumar A, Soprano DR, Parekh HK.
    Cancer Res; 2001 Oct 15; 61(20):7552-5. PubMed ID: 11606393
    [Abstract] [Full Text] [Related]

  • 12. P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines.
    Bradley G, Naik M, Ling V.
    Cancer Res; 1989 May 15; 49(10):2790-6. PubMed ID: 2565764
    [Abstract] [Full Text] [Related]

  • 13. P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin.
    Yang X, Pagé M.
    Oncol Res; 1995 May 15; 7(12):619-24. PubMed ID: 8704279
    [Abstract] [Full Text] [Related]

  • 14. Effects of cytochalasin congeners, microtubule-directed agents, and doxorubicin alone or in combination against human ovarian carcinoma cell lines in vitro.
    Trendowski M, Christen TD, Acquafondata C, Fondy TP.
    BMC Cancer; 2015 Sep 10; 15():632. PubMed ID: 26357852
    [Abstract] [Full Text] [Related]

  • 15. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine.
    Speicher LA, Barone LR, Chapman AE, Hudes GR, Laing N, Smith CD, Tew KD.
    J Natl Cancer Inst; 1994 May 04; 86(9):688-94. PubMed ID: 7908988
    [Abstract] [Full Text] [Related]

  • 16. N-benzyladriamycin-14-valerate (AD 198)-resistant cells exhibit highly selective cross-resistance to other anthracyclines that circumvent multidrug resistance.
    Lothstein L, Hosey LM, Sweatman TW, Koseki Y, Dockter M, Priebe W.
    Oncol Res; 1993 May 04; 5(6-7):229-34. PubMed ID: 7907237
    [Abstract] [Full Text] [Related]

  • 17. Selective modulation of P-glycoprotein-mediated drug resistance.
    Bebawy M, Morris MB, Roufogalis BD.
    Br J Cancer; 2001 Dec 14; 85(12):1998-2003. PubMed ID: 11747345
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract.
    Limtrakul P, Khantamat O, Pintha K.
    Cancer Chemother Pharmacol; 2004 Dec 14; 54(6):525-30. PubMed ID: 15248030
    [Abstract] [Full Text] [Related]

  • 19. Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype.
    Mi Q, Cui B, Silva GL, Lantvit D, Lim E, Chai H, You M, Hollingshead MG, Mayo JG, Kinghorn AD, Pezzuto JM.
    Cancer Res; 2001 May 15; 61(10):4030-7. PubMed ID: 11358822
    [Abstract] [Full Text] [Related]

  • 20. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.
    Baldini N, Scotlandi K, Serra M, Shikita T, Zini N, Ognibene A, Santi S, Ferracini R, Maraldi NM.
    Eur J Cell Biol; 1995 Nov 15; 68(3):226-39. PubMed ID: 8603675
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.